| Symbol | COYA |
|---|---|
| Name | COYA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 5850 SAN FELIPE STREET,SUITE 500, HOUSTON, Texas, 77057, United States |
| Telephone | 800-587-8170 |
| Fax | — |
| — | |
| Website | https://www.coyatherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001835022 |
| Description | Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The companys product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The companys product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. Additional info from NASDAQ: |
Pavao Mark H 🟢 acquired 10.0K shares (1 derivative) of Coya Therapeutics, Inc. (COYA) at $4.53 Transaction Date: Apr 09, 2026 | Filing ID: 149968
Read moreNew Form 3 - Coya Therapeutics, Inc. <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001193125-26-149960 <b>Size:</b> 14 KB
Read moreCoyaTherapeutics - Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Read moreCoya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Read more(75% Positive) COYA THERAPEUTICS, INC. (COYA) Provides Update on step for guiding Coya from its beginnings as a start-up
Read moreCoyaTherapeutics - Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Read moreCoya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Read moreNew Form EFFECT - Coya Therapeutics, Inc. <b>Filed:</b> 2026-03-20 <b>AccNo:</b> 9999999995-26-000895 <b>Size:</b> 1 KB
Read moreCoyaTherapeutics - Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Read moreCoya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Read more